In this retrospective review of allo-SCT for MM going back 34 years, significant improvements were observed in the TRM associated with the introduction of non-myeloablative conditioning. Mortality censored for relapse was 55% among the 144 patients receiving ablative transplants compared with only 18% in the non-myeloablative group. As a result, the survival at 10 years from transplant was significantly superior for non-ablative transplants, 35% compared with 15%. As these two groups were not prospectively studied and were not treated contemporaneously, it is likely that other factors including better antiinfectious prophylaxis and treatment, and the use of PBSCs may Bold numerals refer to number of patients for each heading.